Cancer
Conditions
Brief summary
The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.
Detailed description
Endpoints: Primary: * To determine if erlotinib given orally along with concurrent external beam radiation therapy, prolongs local tumour control as determined by CT evaluation compared to treatment with external beam radiation therapy alone Secondary: * To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy. * To evaluate if erlotinib along with concurrent external beam radiation therapy, improve quality of life as assessed with the EORTC QLQ-C30 and the EORTC QLQ-LC13. * To evaluate if PET-CT examination can be used to predict response to treatment. * To evaluate overall survival in the different groups Trial Design: Open multicenter two-armed randomized phase II trial.
Interventions
DRUGErlotinib
Tarceva daily during radiotherapy course
RADIATIONRadiation
Radiotherapy
Sponsors
Oslo University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 years * Histological or cytological verified NSCLC * Palliative radiotherapy to thorax indicated * ECOG Performance status 0-2 * Fertile patients must use contraception * Signed informed consent * Ability to understand and fill in QoL questionnaires * Capability to take per os medication * Serum bilirubin \< 2 times upper limit of normal (ULN) * AST and ALT \< 2 times ULN (\< 5 times ULN if liver metastases are present) * Creatinine \< 5 times ULN
Exclusion criteria
* Pregnancy or nursing * Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons * No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications * No prior radiotherapy to the same organ / place * No concurrent treatment with other experimental drugs * Known brain metastases in need of radiotherapy * Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with progression in radiation field among patients treated with erlotinib combined with radiotherapy compared to radiotherapy alone | 1 year | Evaluate local control by radiological evaluation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Events grade >3 as Assessed by CTCAE v4.0 | 1 year | To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy. |
| Overall survival will be measured | 1 year | To evaluate overall survival in the different groups |
Countries
Norway
Outcome results
None listed